Immediate Treatment with Bicalutamide 150mg as Adjuvant Therapy Significantly Reduces the Risk of PSA Progression in Early Prostate Cancer
- 1 November 2003
- journal article
- clinical trial
- Published by Elsevier in European Urology
- Vol. 44 (5) , 512-518
- https://doi.org/10.1016/s0302-2838(03)00366-x
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- A Randomised Comparison of Bicalutamide ('Casodex') 150 mg versus Placebo as Immediate Therapy Either Alone or as Adjuvant to Standard Care for Early Non-Metastatic Prostate Cancer First Report from the Scandinavian Prostatic Cancer Group Study No. 6European Urology, 2002
- Comprehensive Comparison of Health-Related Quality of Life After Contemporary Therapies for Localized Prostate CancerJournal of Clinical Oncology, 2002
- The bicalutamide Early Prostate Cancer Program: DemographyUrologic Oncology: Seminars and Original Investigations, 2001
- LONG-TERM HAZARD OF PROGRESSION AFTER RADICAL PROSTATECTOMY FOR CLINICALLY LOCALIZED PROSTATE CANCER: CONTINUED RISK OF BIOCHEMICAL FAILURE AFTER 5 YEARSJournal of Urology, 2000
- Natural History of Progression After PSA Elevation Following Radical ProstatectomyJAMA, 1999
- The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U. S.Cancer, 1998
- PROSTATE-SPECIFIC ANTIGEN AFTER ANATOMIC RADICAL RETROPUBIC PROSTATECTOMYUrologic Clinics of North America, 1997
- Combined finasteride and flutamide therapy in men with advanced prostate cancerUrology, 1996
- Pharmacodynamics and pharmacokinetics of bicalutamide: defining an active dosing regimenUrology, 1996
- Prostate Cancer Clinical Guidelines Panel Summary Report on the Management of Clinically Localized Prostate CancerJournal of Urology, 1995